002252.SZ
上海莱士
SZSE · Healthcare · C 制造业 · CN
CNY 4.81
−0.21%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
27.3x
EV/EBITDA
16.0x
Market Cap
CNY 31.71B
MomentumView details →
1D Return
−0.21%
YTD Return
−22.40%
RSI (14)
48.5
ValuationView details →
P/E (Fwd)
27.3x
EV/EBITDA
16.0x
Market Cap
CNY 31.71B
RSI (14)
48.5
MomentumView details →
1D Return
−0.21%
YTD Return
−22.40%
Similar companies
Latest newsMore news →
Shanghai RAAS stated that Guangxi RAAS is in trial production and has not yet officially commenced production.8d agoShanghai RAAS reported its first-half 2026 results, with net profit attributable to shareholders of 661 million yuan, down 35.80% year-on-year.11d agoShanghai RAAS's subsidiary Guangxi RAAS Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for Protein C, a treatment for congenital protein C deficiency.14d ago